Adial Pharmaceuticals, Inc. Debt Securities, Realized Gain (Loss)
Adial Pharmaceuticals, Inc. (ADIL) reported Debt Securities, Realized Gain (Loss) of $12.24 thousand for the 1-month period ending 2018-02-22, per its 10-K filed 2020-03-20.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesRealizedGainLoss · last filed 2020-03-20
- 2018-02-22: Debt Securities, Realized Gain (Loss) 1 month $12.24K.
| Period end | Debt Securities, Realized Gain (Loss) 1 month |
|---|---|
| 2018-02-22 | $12.24K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |